Is gefitinib a competitive inhibitor?
Gefitinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) and is used to treat non-small-cell lung cancer with EGFR mutations. Gefitinib is known to competitively inhibit CYP2D6 activity.
Is gefitinib an irreversible inhibitor?
All three drugs are irreversible inhibitors, most likely via a covalent bond with the cys773 residue within the EGFR catalytic domain or the cys805 of ERBB2. Like gefitinib, these compounds demonstrate increased killing of NSCLC cells harboring an EGFR mutation, compared with cells expressing wild-type receptor (Fig.
Why was gefitinib withdrawn?
On August 26, 2010, FDA requested that AstraZeneca voluntarily withdraw IRESSA (gefitinib) Tablets from the market, because the postmarketing studies required as a condition of approval under subpart H failed to verify and confirm clinical benefit.
When was gefitinib first discovered?
Development timeline for Iressa
| Date | Article |
|---|---|
| Jul 13, 2015 | Approval FDA Approves Iressa (gefitinib) for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer |
| May 5, 2003 | Approval Astrazeneca Receives FDA Approval for New Cancer Drug Iressa (gefitinib, ZD1839) |
When was Iressa FDA approved?
On May 5, 2003, gefitinib (Iressa), ZD1839) 250-mg tablets received accelerated approval by the U.S. Food and Drug Administration as monotherapy treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of both platinum-based and docetaxel chemotherapies.
When was Tarceva FDA?
On May 14, 2013, the FDA approved Tarceva® (erlotinib) tablets for the initial (first-line) treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have been identified to have certain epidermal growth factor receptor (EGFR) mutations by an FDA-approved test.
What generation is gefitinib?
First-generation EGFR TKIs (gefitinib, erlotinib and icotinib) reversibly bind to EGFR and inhibit the binding of ATP to the TK domain. This block hampers cell proliferation, ultimately leading to cell death (11).
How to obtain human hcc827 GR5 NSCLC cells?
Human HCC827 GR5 NSCLC cell line was kindly provided by Dr P. Jänne (Dana-Farber Cancer Institute, Boston MA) and it was obtained from gefitinib-sensitive EGFR exon 19 mutant HCC827 cell line by exposing these cells to increasing concentration of gefitinib for 6 months as previously described [13].
Is the EGFR mutation involved in resistance to gefitinib?
Conclusions: The T790M mutation in the EGFR is relatively common in the patients with acquired resistance to gefitinib. However, mechanisms other than T790M, MET, and HGF status are involved in resistance to gefitinib. Copyright 2009 Elsevier Ireland Ltd.
What do we know about the secondary mutations in gefitinib-resistant tumors?
In 7 of 10 patients, the gefitinib-resistant tumors had a secondary T790M mutation, which was not detected in the gefitinib pre-treatment tumors. In one patient, only one of the 4 gefitinib-resistant tumors showed the T790M mutation. Neither other novel secondary mutations of EGFR nor the K-ras were observed in their gefitinib-resistant tumors.